AVRO News and Press, AVROBIO Inc. From 01/19/21

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Diana M. Escolar, M.D., FAAN, as chief medical officer. Dr. Escolar brings deep expertise across rare dise...

AVROBIO , Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present virtually at the ICR Conference 2021 at 11:30 a.m. ET on Thursday, ...

AVROBIO, Inc. is a clinical-stage gene therapy biotechnology company focused on developing single-dose curative ex-vivo lentiviral-based gene therapies for rare diseases. AVROBIO is developing a pipeline of six gene-therapeutics covering Fabry's disease (AVR-RD-01), Gau...

AVROBIO is developing gene therapies for lysosomal disorders where lifelong enzyme replacement therapy is the SoC. Early stage data shows promise. If successful, it is looking at a multibillion dollar market. For further details see: AVROBIO: Undercovered Gene Therapy De...

Gainers: Kaixin Auto (KXIN) +104%.FTS International (FTSI) +44%.Ayro (AYRO) +42%.Blink Charging (BLNK) +31%.Dada Nexus (DADA) +30%.Ideanomics (IDEX) +23%.Ra Medical Systems (RMED) +22%.SPI Energy (SPI) +21%.Canaan (CAN) +20%.Longview Acquisition (LGVW) +20%.Losers: Tantech (TAN...

Gainers: Titan Pharmaceuticals (TTNP) +31%, Idera Pharmaceuticals (IDRA) +27%, Mesoblast (MESO) +20%, 22nd Century Group (XXII) +14%, Genfit (GNFT) +13%.Losers: AVROBIO (AVRO) -14%, Stealth BioTherapeutics (MITO) -14%, Kazia Therapeu...

Avrobio (AVRO) has priced its public offering of 5M common shares at $15.00/share, for gross proceeds of ~$75M.Underwriters' over-allotment is an additional 750K shares. Net proceeds will be used to fund programs in Fabry disease, cystinosis, Gaucher disease type 1, Hunter syndrome, Pompe dis...

AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. Gross proceeds from the underwritten public offering will t...

AVROBIO (AVRO) intends to offer $75M of its common stock in an underwritten public offering. Underwriters have an option to purchase up to $11.25M of additional shares.Number of shares are price are yet to be determined. For further details see: AVROBIO readies $75M equity offering

Avrobio (AVRO) announces positive data across its clinical programs in Gaucher disease type 1, Fabry disease and cystinosis. New clinical updates announced today include:AVR-RD-02 for Gaucher disease type 1: Positive early reductions in plasma lyso-Gb1 and chitotriosidase activity at three mo...